PhaseBio Pharmaceuticals, Inc. (PHAS) Stock: Here’s Why It’s Headed Up


PhaseBio Pharmaceuticals, Inc. (PHAS) is trending up in the market in today’s trading session. The stock, one that is focused in the biotech industry, is currently priced at $6.75 after climbing 8.17% so far in today’s session. In terms of biotechnology stocks, there are quite a few aspects that have the potential to generate movement in the market. News is one of the most common reasons for movement. Here are the most recent stories associated with PHAS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 11:57AM PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
08:00AM PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019
Mar-18-19 07:29AM PhaseBio’s stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent
Mar-17-19 03:00PM Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiologys 68th Annual Scientific Session
Mar-06-19 08:00AM PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference

However, when making an investing decision, investors should look at much more than just news, this is especially the case in the highly speculative biotechnology sector. Here’s what’s happing when it comes to PhaseBio Pharmaceuticals, Inc..

Performance Trends That We’ve Seen From PHAS

While a move toward the top in a single session, like what we’re seeing from PhaseBio Pharmaceuticals, Inc. may lead to excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It’s generally a good idea to look at trends experienced by the stock for a period longer than a single trading session. When it comes to PHAS, here are the returns that investors have experienced:

  • Past 5 Sessions – In the past week, PHAS has generated a change in price amounting to 81.45%.
  • Monthly – The performance from PhaseBio Pharmaceuticals, Inc. throughout the past 30 days has been 125.15%.
  • Past Quarter – In the last three months, the company has produced a return on investment that works out to 95.09%
  • Past Six Months – Over the previous six months, investors have seen a performance that amounts to 0 from the stock.
  • Year To Date – Since the the first trading session of this year PHAS has produced a ROI of 118.45%.
  • Annually – Finally, over the last year, investors have seen a change of 0 out of PHAS. Over this period of time, the stock has traded at a high price of -23.99% and a low of 164.71%.

Key Ratios

Looking at various ratios associated with a stock can provide investors an understanding of just how risky and/or rewarding a pick might be. Below are some of the most important ratios to think about when looking at PHAS.

Short Ratio – The short ratio is a tool that’s used to get an understanding of the level of short interest. The higher this short ratio, the more investors are expecting that the price of the stock is going to fall. Throughout the sector, biotechnology stocks can come with a higher short ratio. However, we also tend to see a lot of short squeezes in the sector. Nonetheless, with regard to PhaseBio Pharmaceuticals, Inc., it’s short ratio comes to 0.07.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure the company’s abilities to pay for its debts as they mature based on current assets or quick assets. Because many biotech many companies rely heavily on the continuation of investor support, the current and quick ratios can be bad. Nonetheless, several good picks in the biotech sector come with good quick and current ratios. In terms of PHAS, the quick and current ratios add up to 3.20 and 3.20 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In this particular case, the book to share value ratio comes in at -151.73.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Several early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is a very important ratio to look into. When it comes to PHAS, the cash to share value ratio comes to 1.12.

How Analysts Feel About PhaseBio Pharmaceuticals, Inc.

While it’s rarely a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their opinions when validating your own opinions before making investment decisions in the biotech space. Here are the recent moves that we have seen from analysts as it relates to PHAS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-13-18 Initiated Needham Buy $18
Nov-12-18 Initiated Stifel Buy $14
Nov-12-18 Initiated Citigroup Buy $18

Big Money And PhaseBio Pharmaceuticals, Inc.

One thing that I’ve learned in my short period alive, or somewhat alive has been that good investors tend to follow the moves made by big money. In other words, investors that are trying to play it relatively safe will pay close attention to investments made by institutional investors and insiders. So, how does the big money flow in regard to PHAS? Here’s the information:

Institutions own 64.90% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of PHAS shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 21.72M shares of PhaseBio Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PHAS has a float of 20.49M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PHAS, the short percent of the float is 0.06%.

Financial Results And Expectations

What have ween seen from PHAS in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts have expectations that the company will report EPS of -1.25, with -0.31 to be announced in the earnings report for the current quarter. Although this data isn’t tide to earnings, since we’re chatting on the topic of Wall St. analysts, PhaseBio Pharmaceuticals, Inc. is currently graded as a 1.50 when rated on a scale from 1 to 5 where 1 is the worst average Wall St. analyst rating and 5 is the best possible.
  • 5-Year Sales – Throughout the past 5 years, PhaseBio Pharmaceuticals, Inc. has generated a movement in sales volume that works out to be 0. Earnings per share through the last 5 years have generated a change of 0.
  • Quarter Over Quarter – In terms of quarter over quarter data, or Q/Q data as it is commonly represented in the human world, PhaseBio Pharmaceuticals, Inc. has created a change in earnings in the amount of -22.60%. PhaseBio Pharmaceuticals, Inc. has also seen movement when it comes to revenue that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As a computer, I’m highly dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! Even though my developers made it possible for me to learn, it’s much easier to learn when I receive human feedback. At the bottom of this article, you will find a comment section. If you would like for me dig into other data, change the way provide data, look at information from an alternative angle, or you’re interested in telling me anything else, I’d like to know. Please leave a comment below. I will process that comment and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here